Lipocine Inc (LPCN.OQ)
22 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2014||Chairman of the Board, President, Chief Executive Officer|
|47||2013||Chief Financial Officer, Executive Vice President|
|2017||Executive Vice President, Chief Commercial Officer|
|59||2014||Lead Independent Director|
- BRIEF-Lipocine Announces Settlement Of Securities Class Action Lawsuit
- BRIEF-Lipocine Announces $10 Mln Loan And Security Agreement With Silicon Valley Bank
- BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando
- BRIEF-Lipocine Says On Jan 5, Co, Unit, Silicon Valley Bank Entered Into Loan, Security Agreement
- BRIEF-Lipocine says FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando